AMEX · CATX
Healthcare · Medical - Devices
$3.21
Up+$0.09 (+2.80%)
Updated Aug 21, 2026, 9:18 PM
SID Score
4.4/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CATX does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CATX.
CATX research
Company profile and research snapshot.
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 19, 2026 | BMO Capital | Outperform | — |
| Aug 14, 2026 | B of A Securities | Neutral | — |
| Aug 11, 2026 | Piper Sandler | Overweight | — |
| May 5, 2026 | Wedbush | Outperform | — |
| May 5, 2026 | BTIG | Buy | — |
No generated briefing is available yet.
Benzinga · Aug 19, 2026
BMO Capital analyst David Lebowitz initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Outperform rating and announces Price Target of $11.
Benzinga · Aug 14, 2026
B of A Securities analyst Alec Stranahan maintains Perspective Therapeutics (AMEX:CATX) with a Neutral and lowers the price target from $6 to $5.
Benzinga · Aug 11, 2026
Piper Sandler analyst Biren Amin maintains Perspective Therapeutics (AMEX:CATX) with a Overweight and lowers the price target from $16 to $14.
Benzinga · Aug 10, 2026
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.22) per share which beat the analyst consensus estimate of $(0.26) by 15.38 percent. This is a 26.67 percent increase over losses of $(0.30) per
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CATX.
